vs
Hillenbrand, Inc.（HI）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是Hillenbrand, Inc.的1.1倍（$622.0M vs $550.2M），Royalty Pharma plc净利率更高（34.4% vs -0.4%，领先34.8%），Royalty Pharma plc同比增速更快（4.8% vs -22.2%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -16.3%）
希伦布兰德是一家全球化多元化工业企业，设计、生产及销售专用加工设备与耐用工业解决方案，服务食品饮料、农业、制造、废弃物管理等领域，业务覆盖北美、欧洲及亚太地区。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
HI vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.1倍
$550.2M
营收增速更快
RPRX
高出26.9%
-22.2%
净利率更高
RPRX
高出34.8%
-0.4%
两年增速更快
RPRX
近两年复合增速
-16.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $550.2M | $622.0M |
| 净利润 | $-2.2M | $214.2M |
| 毛利率 | 33.4% | — |
| 营业利润率 | -2.2% | 62.4% |
| 净利率 | -0.4% | 34.4% |
| 营收同比 | -22.2% | 4.8% |
| 净利润同比 | -134.4% | 2.9% |
| 每股收益（稀释后） | — | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HIRPRX
| Q4 25 | $550.2M | $622.0M | ||
| Q3 25 | $652.1M | $609.3M | ||
| Q2 25 | $598.9M | $578.7M | ||
| Q1 25 | $715.9M | $568.2M | ||
| Q4 24 | $706.9M | $593.6M | ||
| Q3 24 | $837.6M | $564.7M | ||
| Q2 24 | $786.6M | $537.3M | ||
| Q1 24 | $785.3M | $568.0M |
净利润HIRPRX
| Q4 25 | $-2.2M | $214.2M | ||
| Q3 25 | $75.7M | $288.2M | ||
| Q2 25 | $1.9M | $30.2M | ||
| Q1 25 | $-40.9M | $238.3M | ||
| Q4 24 | $6.4M | $208.2M | ||
| Q3 24 | $14.6M | $544.0M | ||
| Q2 24 | $-248.9M | $102.0M | ||
| Q1 24 | $6.1M | $4.8M |
毛利率HIRPRX
| Q4 25 | 33.4% | — | ||
| Q3 25 | 34.8% | — | ||
| Q2 25 | 33.8% | — | ||
| Q1 25 | 33.0% | — | ||
| Q4 24 | 33.2% | — | ||
| Q3 24 | 34.4% | — | ||
| Q2 24 | 33.9% | — | ||
| Q1 24 | 31.9% | — |
营业利润率HIRPRX
| Q4 25 | -2.2% | 62.4% | ||
| Q3 25 | — | 70.1% | ||
| Q2 25 | 1.8% | 36.3% | ||
| Q1 25 | -6.2% | 94.0% | ||
| Q4 24 | 2.2% | 60.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | -32.7% | 50.2% | ||
| Q1 24 | 1.6% | -13.0% |
净利率HIRPRX
| Q4 25 | -0.4% | 34.4% | ||
| Q3 25 | 11.6% | 47.3% | ||
| Q2 25 | 0.3% | 5.2% | ||
| Q1 25 | -5.7% | 41.9% | ||
| Q4 24 | 0.9% | 35.1% | ||
| Q3 24 | 1.7% | 96.3% | ||
| Q2 24 | -31.6% | 19.0% | ||
| Q1 24 | 0.8% | 0.8% |
每股收益（稀释后）HIRPRX
| Q4 25 | — | $0.49 | ||
| Q3 25 | $1.07 | $0.67 | ||
| Q2 25 | $0.03 | $0.07 | ||
| Q1 25 | $-0.58 | $0.55 | ||
| Q4 24 | $0.09 | $0.46 | ||
| Q3 24 | $0.20 | $1.21 | ||
| Q2 24 | $-3.53 | $0.23 | ||
| Q1 24 | $0.09 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $173.1M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $1.4B | $9.7B |
| 总资产 | $4.5B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资HIRPRX
| Q4 25 | $173.1M | $618.7M | ||
| Q3 25 | $164.8M | $938.9M | ||
| Q2 25 | $162.8M | $631.9M | ||
| Q1 25 | $458.4M | $1.1B | ||
| Q4 24 | $208.0M | $929.0M | ||
| Q3 24 | $199.3M | $950.1M | ||
| Q2 24 | $223.8M | $1.8B | ||
| Q1 24 | $224.4M | $843.0M |
总债务HIRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | $1.5B | $8.9B | ||
| Q2 25 | $1.7B | $8.0B | ||
| Q1 25 | $1.9B | $7.6B | ||
| Q4 24 | $1.9B | $7.6B | ||
| Q3 24 | $1.9B | $7.6B | ||
| Q2 24 | $2.1B | $7.6B | ||
| Q1 24 | $2.1B | $6.1B |
股东权益HIRPRX
| Q4 25 | $1.4B | $9.7B | ||
| Q3 25 | $1.4B | $9.6B | ||
| Q2 25 | $1.3B | $9.5B | ||
| Q1 25 | $1.3B | $9.8B | ||
| Q4 24 | $1.4B | $10.3B | ||
| Q3 24 | $1.4B | $10.3B | ||
| Q2 24 | $1.4B | $9.8B | ||
| Q1 24 | $1.7B | $9.9B |
总资产HIRPRX
| Q4 25 | $4.5B | $19.6B | ||
| Q3 25 | $4.5B | $19.3B | ||
| Q2 25 | $4.7B | $18.3B | ||
| Q1 25 | $4.8B | $17.6B | ||
| Q4 24 | $5.1B | $18.2B | ||
| Q3 24 | $5.2B | $18.0B | ||
| Q2 24 | $5.3B | $17.7B | ||
| Q1 24 | $5.6B | $16.1B |
负债/权益比HIRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | 1.10× | 0.93× | ||
| Q2 25 | 1.27× | 0.84× | ||
| Q1 25 | 1.44× | 0.78× | ||
| Q4 24 | 1.38× | 0.74× | ||
| Q3 24 | 1.33× | 0.74× | ||
| Q2 24 | 1.48× | 0.78× | ||
| Q1 24 | 1.28× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-27.4M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-31.6M | — |
| 自由现金流率自由现金流/营收 | -5.7% | — |
| 资本支出强度资本支出/营收 | 0.8% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $7.8M | — |
8季度趋势，按日历期对齐
经营现金流HIRPRX
| Q4 25 | $-27.4M | $827.1M | ||
| Q3 25 | $67.7M | $702.6M | ||
| Q2 25 | $-1.5M | $364.0M | ||
| Q1 25 | $1.3M | $596.1M | ||
| Q4 24 | $-11.3M | $742.5M | ||
| Q3 24 | $166.5M | $703.6M | ||
| Q2 24 | $45.6M | $658.2M | ||
| Q1 24 | $3.2M | $664.6M |
自由现金流HIRPRX
| Q4 25 | $-31.6M | — | ||
| Q3 25 | $58.6M | — | ||
| Q2 25 | $-11.2M | — | ||
| Q1 25 | $-8.0M | — | ||
| Q4 24 | $-21.5M | — | ||
| Q3 24 | $153.4M | — | ||
| Q2 24 | $29.7M | — | ||
| Q1 24 | $-9.6M | — |
自由现金流率HIRPRX
| Q4 25 | -5.7% | — | ||
| Q3 25 | 9.0% | — | ||
| Q2 25 | -1.9% | — | ||
| Q1 25 | -1.1% | — | ||
| Q4 24 | -3.0% | — | ||
| Q3 24 | 18.3% | — | ||
| Q2 24 | 3.8% | — | ||
| Q1 24 | -1.2% | — |
资本支出强度HIRPRX
| Q4 25 | 0.8% | — | ||
| Q3 25 | 1.4% | — | ||
| Q2 25 | 1.6% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | 1.6% | — | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 1.6% | — |
现金转化率HIRPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | 0.89× | 2.44× | ||
| Q2 25 | -0.79× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | -1.77× | 3.57× | ||
| Q3 24 | 11.40× | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | 0.52× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HI
| Transferred At Point In Time | $256.5M | 47% |
| Transferred Over Time | $207.1M | 38% |
| Molding Technology Solutions | $86.6M | 16% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
